{"name":"Achaogen, Inc.","slug":"achaogen-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":8728000,"revenueGrowth":331,"grossMargin":0,"rdSpend":102959000,"netIncome":-186512000,"cash":82290000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2018"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"ACHN-383","genericName":"ACHN-383","slug":"achn-383","indication":"Other","status":"phase_1"},{"name":"ACHN-789","genericName":"ACHN-789","slug":"achn-789","indication":"Other","status":"phase_1"},{"name":"ACHN-490 Injection","genericName":"ACHN-490 Injection","slug":"achn-490-injection","indication":"Other","status":"phase_1"}]},{"name":"Infectious Disease","slug":"infectious-disease","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"antibiotic of Investigator's choice","genericName":"antibiotic of Investigator's choice","slug":"antibiotic-of-investigator-s-choice","indication":"Serious gram-negative bacterial infections (investigator's choice indication)","status":"phase_3"}]}],"pipeline":[{"name":"ACHN-383","genericName":"ACHN-383","slug":"achn-383","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACHN-789","genericName":"ACHN-789","slug":"achn-789","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ACHN-490 Injection","genericName":"ACHN-490 Injection","slug":"achn-490-injection","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"antibiotic of Investigator's choice","genericName":"antibiotic of Investigator's choice","slug":"antibiotic-of-investigator-s-choice","phase":"phase_3","mechanism":"This antibiotic inhibits bacterial protein synthesis by binding to the bacterial ribosome.","indications":["Serious gram-negative bacterial infections (investigator's choice indication)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBnUmhPUjVHZVpqRFJJN0pBNzZEV0VhXzhIb1VoUmlGVWNyMFBOR3hnNlFnelNQd1BLby1rOGdKUG5wYUIwUjl1Um51MzFwQzJoYkFzQ3ZLSHJaWDhodldR?oc=5","date":"2024-07-20","type":"pipeline","source":"nature.com","summary":"Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic investment ecosystem - nature.com","headline":"Novel insights from financial analysis of the failure to commercialise plazomicin: Implications for the antibiotic inves","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxOTVc5dFN0bndfVlA5WjdkSnBFUDFST2tyZGNPVXNPOHJXSW5DQUd2aWRrdkM5ZTFiSWJlWDVfY2RaUVJIdHdvaHAzOWdKR2p1MHdGTTFad0xzUF85R29zd1lSM0RiYWlSd2h2d29KbUQzMEZJNGRCVVNTV1p0X2RheHd2WUZCeE03cnhB?oc=5","date":"2022-01-07","type":"pipeline","source":"Pharma Voice","summary":"Meet the Chief Scientific Officers - Pharma Voice","headline":"Meet the Chief Scientific Officers","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxPQUlBbmNMZnRwMGZKaGx0V1lBdGIwa2lmRWN2enNHTTNOOUhTOG5xUmZzdjFnUGlxMWJaMnlXd0pCa3Y3WXl0bUdsSFVieE0yeU9tUUtCRFZkSVQ3OWMyOG1ZTElMUHVBeGVzZ08zMTdIQTgta20tbkZJa21uY0M2MUFieUVtQzYw?oc=5","date":"2019-11-19","type":"pipeline","source":"BioPharma Dive","summary":"The running list of 2019 biopharma bankruptcies - BioPharma Dive","headline":"The running list of 2019 biopharma bankruptcies","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimgFBVV95cUxNRHJxd1kxTkEyeUJTR3d1Rk9OWVBJbGR6RURHQWJqVm02YlZRUzhudVR6ZlRIX05JR2tiYUdsM2ZneFJpdjUteXdWQmE2aV9ZNGRZTU9qYzdZcXFkUG9EWV9kZUlTM1l0S2NuNVVSZmtvOUFEVm1ydU1kcEwyV1lUVEl2dnRUWW9rZG1FUVBBM0lEUzY3STIzdmt3?oc=5","date":"2019-10-23","type":"deal","source":"wsj.com","summary":"Achaogen Taps New Buyer for Antibacterial Drug Rights - wsj.com","headline":"Achaogen Taps New Buyer for Antibacterial Drug Rights","sentiment":"neutral"},{"date":"2019-07-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K PLAZO APA CLOSING","headline":"SEC 8-K: 8-K PLAZO APA CLOSING","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPbS0wOW5VSTNuRndEdVdJd2dhekhYb1NKWFhhUDFwdnRTU2NZa0lkTTgxcG4zX0l4c0daQlBEeWpRUWpuQzRPTGNvU1c5U1k2LUxVQkdSRGF2THdld283QnAwVFQ4VXQxU3ZLYk5Qby1OOGZXZV9uUVc3LW9zYVZjU3RqNkFoNnEtVTNkSjduWjYteGdMUTJYcTdZUEd1eGhL?oc=5","date":"2019-07-25","type":"deal","source":"BioSpectrum Asia","summary":"Cipla USA acquires worldwide rights for UTI drug - BioSpectrum Asia","headline":"Cipla USA acquires worldwide rights for UTI drug","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxOUzVOeGJSR1pDcm9oWS1XaDhTNzBCZ3dEc0lxX0Z5bVV0UjBhNVJFZTNmZm5GMmdlU3VJcVh3dVdBVVRVaG9fTW1mWFpHTFNMSmtIdmlidzF3SWNVOHJXQ0t4ak9GUV91b1RYV1g1Z1BVYTY2aWlFeTVmdmZGM3ZCRnBza3JNSGc1VWpSS1BfWHRQNzdQZUV4dC1IU1BjM2dGTEpfaUlGbDkzNkpKYTVCTE5qelRwbkF6Yzl5QUNQN3ZqaHc2TVhqM2lqRUFXb1JEbFdjZlZRX0RlU1RfS0gxNk9fdzg?oc=5","date":"2019-07-24","type":"pipeline","source":"PR Newswire","summary":"Cipla USA Furthers AMR Stewardship With Acquisition of Key Anti-infective ZEMDRI™ (IV Plazomicin) - PR Newswire","headline":"Cipla USA Furthers AMR Stewardship With Acquisition of Key Anti-infective ZEMDRI™ (IV Plazomicin)","sentiment":"neutral"},{"date":"2019-07-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K PLAZO APA AMEND","headline":"SEC 8-K: 8-K PLAZO APA AMEND","sentiment":"neutral"},{"date":"2019-06-28","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-06-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-06-07","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-06-05","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2019-05-14","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K KEIP, KERP","headline":"SEC 8-K: 8-K KEIP, KERP","sentiment":"neutral"},{"date":"2019-05-06","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K - IOR, FORM 25, BID PROCEDURES","headline":"SEC 8-K: 8-K - IOR, FORM 25, BID PROCEDURES","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxNem5oblJWWm9fbHB3LWRKam1GUzUxZmtFNjhzRHRkTjNubjRmYTU1eFJ3TFlqM2RYR3dpN0VKd2ZKVzBtZXVWYmxIVEFZbk5mVUZVendKMzBKdjdOR1Y3QmRENXpUaTMxSGJDNFRSRnhFYUx2MDBiWlE5a3B2Y19EVlc4VEZIUkc4UEZ5cFR3Wk5sVTBYVzgtZHk4SFlya2ZId2pqQTVLVDQ3RURfY2Yw?oc=5","date":"2019-04-16","type":"pipeline","source":"CIDRAP","summary":"Achaogen bankruptcy raises worry over antibiotic pipeline - CIDRAP","headline":"Achaogen bankruptcy raises worry over antibiotic pipeline","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_1":3,"phase_3":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar","revenue":8728000,"revenuePeriod":"2018-12-31","revenueHistory":[{"value":8728000,"period":"2018-12-31"},{"value":2025000,"period":"2018-12-31"},{"value":1998000,"period":"2018-09-30"},{"value":2562000,"period":"2018-06-30"},{"value":2143000,"period":"2018-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":102959000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-186512000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":82290000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"ciks":null,"lastFiledAt":null},"yahoo":null}